WO2017099413A1 - Composition comprenant un extrait de fruit de rosa multiflora traité par enzyme en tant que substance active pour prévenir ou traiter une maladie immunologique médiée par th2 - Google Patents

Composition comprenant un extrait de fruit de rosa multiflora traité par enzyme en tant que substance active pour prévenir ou traiter une maladie immunologique médiée par th2 Download PDF

Info

Publication number
WO2017099413A1
WO2017099413A1 PCT/KR2016/013971 KR2016013971W WO2017099413A1 WO 2017099413 A1 WO2017099413 A1 WO 2017099413A1 KR 2016013971 W KR2016013971 W KR 2016013971W WO 2017099413 A1 WO2017099413 A1 WO 2017099413A1
Authority
WO
WIPO (PCT)
Prior art keywords
enzyme
treated
extract
youngsil
composition
Prior art date
Application number
PCT/KR2016/013971
Other languages
English (en)
Korean (ko)
Inventor
손동화
신희순
도정룡
이소영
최대운
정선영
시혜정
권다애
백수연
엄지은
Original Assignee
한국식품연구원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020160160179A external-priority patent/KR101843573B1/ko
Application filed by 한국식품연구원 filed Critical 한국식품연구원
Publication of WO2017099413A1 publication Critical patent/WO2017099413A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Definitions

  • the present invention relates to a composition for the prevention or treatment of Th2-mediated immune diseases, comprising an enzyme-treated Youngsil extract as an active ingredient.
  • Thl / Th2 balance The immune balance regulated by cytokines produced by Thl (type 1 helper T) and Th2 (type 2 helper T) cells is called Thl / Th2 balance, and Thl cells are important for the regulation of cellular immunity. Plays an important role in humoral regulation In steady state, the cytokine centered on IFN- ⁇ , which is important for the differentiation of Thl, and the cytokine centered on IL-4, which is important for the differentiation of Th2, interfere with each other to maintain a constant Thl / Th2 balance. If the balance is off, a variety of immune diseases can occur. For example, when it is biased by Thl, cellular immunity is revived to increase infection resistance, and when it is biased by Th2, infection resistance is decreased, and conversely, allergy is enhanced.
  • Allergy is a malfunction of the immune system, a substance that does not affect the average person and causes hypersensitivity reactions such as hives, itching, runny nose, and cough only in certain people.
  • Allergic reactions are traditionally divided into four classes based on expression time and type, with type I-III being the humoral immune response involving antibodies (immediate type) and type IV with the cellular immune response directly involving cells. Delay type). Most allergic reactions include type I asthma, rhinitis, conjunctivitis, food and drug allergies, and atopic dermatitis. In severe cases, anaphylaxis may be induced.
  • Type I immediate hypersensitivity is divided into two stages, the first stage of which is a Th1 cell reaction that produces IL-12 and IFN- ⁇ that inhibits the release of IgE and IgG1 and increases the secretion of IgG2a by the invasion of allergens. And the balance of Th2 (type2 helper T) cell responses that produce IL-4, IL-5, and IL-13 are inclined toward Th2, and IL-4, IL-13, etc. are secreted due to the excessive immune response of Th2, As a result, IgE-specific antibodies produced by B cells are attached to the surface of mast cells or basophils, and allergens are sensitized.
  • Th2 type2 helper T
  • the second stage of allergic development is divided into early reaction and late reaction, and the initial reaction is reinvading allergens into the body to stimulate mast cells and induce degranulation reaction.
  • Vasodilation due to released histamine, lipid metabolites and cytokines The back reaction occurs when neutrophils, eosinophils, macrophages, Th2 cells, basophils, etc. are activated by infiltration of the tissues, causing inflammation and causing atopic dermatitis, rhinitis, and asthma.
  • histamine is the most well known factor and is used as an important indicator of allergic symptoms related to immediate hypersensitivity.
  • Youngsil (Rosae multiflorae Fructus) is a fruit of the brier, which belongs to the family Rosaceae, and is commonly distributed in Korea and Japan. The appearance is spherical or oval, the outer surface is red or dark reddish brown, the pentagonal pistil remains at the end of the fruit, has a slightly sour smell and tastes a little sweet. Youngsil does not urinate well, or swelling, insomnia, decreased sexual function, boils, swelling, etc. It is effective in promoting blood circulation and removing poison. Pharmacological actions have been reported to coronary atherosclerosis, mouse life extension, lipid and protein metabolism improvement, and atherosclerosis formation inhibition.
  • the present inventors studied the anti-allergic activity enhancing effect after the enzyme treatment in Youngsil extract, and completed the present invention based on this.
  • the present inventors have studied diligently to enhance the prophylactic or therapeutic effect of diseases caused by Th2 immune response such as allergy to Youngsil extract.
  • enzyme-treated Youngsil extract is IL-4 as compared to extract without enzyme.
  • the present invention was completed by confirming that the IgE production inhibitory activity is significantly enhanced.
  • an object of the present invention is to provide a composition for preventing, ameliorating, or treating Th2-mediated immune disease, comprising an enzyme-treated Youngsil extract as an active ingredient.
  • the present invention provides a pharmaceutical composition for preventing or treating Th2-mediated immune disease, comprising as an active ingredient the enzyme treatment Youngsil (Rosae multiflorae Fructus) extract.
  • the Th2-mediated immune disease may be an allergic disease.
  • the enzyme may be beta-glucosidase ( ⁇ -glucosidase).
  • the extract is a group consisting of water, C 1 to C 4 lower alcohol, ethyl acetate, acetone, butyl acetate, 1,3-butylene glycol, methylene chloride, and a mixed solvent thereof It may be extracted with a solvent selected from.
  • the composition may inhibit the production of interleukin-4 (IL-4).
  • IL-4 interleukin-4
  • the composition may inhibit the production of immunoglobulin E (IgE).
  • IgE immunoglobulin E
  • the present invention provides a health functional food composition for improving Th2-mediated immune disease, comprising an enzyme-treated Youngsil (Rosae multiflorae Fructus) extract as an active ingredient.
  • the present invention provides a cosmetic composition for improving Th2-mediated immune disease, comprising an enzyme-treated Youngsil (Rosae multiflorae Fructus) extract as an active ingredient.
  • the present invention also provides a method for preventing or treating a Th2-mediated immune disease, comprising administering the pharmaceutical composition to a subject.
  • the present invention also provides a use of the pharmaceutical composition for the prophylaxis or treatment of Th2-mediated immune diseases.
  • the composition according to the present invention can maximize the anti-allergic effect of the enzyme treatment Youngsil extract as an active ingredient, Youngsil extract.
  • Youngsil extract as an active ingredient, Youngsil extract.
  • the inventors of the present invention treated the enzyme-treated Youngsil extract on splenocytes of mice immunized with OVA, which significantly enhanced IL-4 production inhibitory activity compared to the enzyme-treated Youngsil extract, and the enzyme-treated Youngsil in vivo . It was confirmed that blood IgE content of mice immunized with OVA was significantly decreased by oral administration of the extract.
  • the composition according to the present invention is a safe treatment for the prevention, improvement, or treatment of Th2-mediated immune diseases, health functional foods, and the development of cosmetics, etc. It is expected to be usefully used.
  • mice spleen cells immunized with OVA at different concentrations of each of the Youngsil extracts (Youngsil water extract, Youngsil room temperature alcohol extract, and Youngsil alcohol extract) with or without beta-glucosidase, After culturing the cells for 72 hours, the amount of IL-4 from the culture was measured by ELISA.
  • Youngsil extracts Youngsil water extract, Youngsil room temperature alcohol extract, and Youngsil alcohol extract
  • Figure 2 is a result of oral administration of the control of the Youngsil extract or enzyme-treated Youngsil extract as a control to the mice with OVA, the blood IgE content of the mice was measured by ELISA (Youngsil: Youngsil extract administration group, ⁇ -glucosidase treatment: enzyme treatment Youngsil extract administration group).
  • the present invention relates to Youngsil extracts whose activity is enhanced through enzyme treatment and their use.
  • the present invention provides a pharmaceutical composition for preventing or treating Th2-mediated immune disease, comprising an enzyme-treated Youngsil (Rosae multiflorae Fructus) extract as an active ingredient.
  • prevention means any action that inhibits or delays the onset of Th2-mediated immune disease by administration of a pharmaceutical composition according to the present invention.
  • treatment refers to any action in which symptoms for Th2-mediated immune disease improve or benefit altered by administration of the pharmaceutical composition according to the present invention.
  • Youngsil a natural material used in the present invention, belongs to the family Rosaceae and is a fruit of the brier commonly grown in Korea and Japan. It is the appearance that remains. It has a slightly sour smell and tastes a little, and it is not used to urinate well, or is used for swelling, insomnia, decreased sexual function, boil, swelling, and promotes blood circulation and removes poison. In addition, pharmacological actions such as coronary artery dilatation, mouse life extension, lipid, protein metabolism improvement, and atherosclerosis suppression are reported. In the present invention, Youngsil may be used as it is without extracting the fruit as a raw material, it may be used in powder form.
  • Th2-mediated immune disease refers to a disease involving allergens, particularly IgE and mast cells by the production and activation of Th2 cells, including allergy, and more specifically, atopic dermatitis.
  • Skin diseases including dermatitis, acute and chronic allergic rhinitis, asthma, food and drug allergies, and anaphylaxis, and the like, but are not limited thereto.
  • enzyme refers to a protein-based high molecular organic catalyst produced by living cells as a catalyst for chemical reactions in living organisms.
  • Various kinds of enzymes exist in the cells of all living things such as animals and plants, and they are involved in the chemical reactions of living things. Since enzymes are very complex in their chemical structure, they are classified according to the type of substrate or the type of reaction, and according to the type of reaction, hydrolase, transferase, lyase and synthetase, Are classified as isomerases.
  • Enzymes are used in a wide variety of applications, including pharmaceuticals, large-scale utilization of starch saccharification by amylase, cheese production, fruit juice purification, textile industry, and the synthesis of vitamins and amino acids.
  • beta-glucosidase was used to enhance activity of Youngsil.
  • the beta-glucosidase is an enzyme that acts on a ⁇ 1-> 4 bond connecting two glucose or glucose-substituted molecules and is a cellulose or an associated polysaccharide.
  • Enzymatically treated Youngsil extract of the present invention comprises the steps of obtaining Youngsil extract; And it can be prepared by a method comprising the step of reacting by adding an enzyme to the Youngsil extract. Specifically, the step of adding and reacting the enzyme may be performed at 37 ° C. for 15 hours to 40 hours, more preferably 20 to 30 hours.
  • the Youngsil extract can be extracted according to a conventional method known in the art for extracting the extract from natural products, that is, using a conventional solvent under the conditions of conventional temperature, pressure.
  • the Youngsil extract in the present invention is at least one selected from the group consisting of water, alcohol having 1 to 4 carbon atoms, ethyl acetate, acetone, butyl acetate, 1,3-butylene glycol, methylene chloride, and a mixed solvent thereof
  • the extraction can be carried out using a solvent, preferably extraction with water or ethanol.
  • the extraction method of Youngsil extract may be extracted through various methods such as room temperature extraction, hot water extraction, cold extraction, reflux extraction, microwave extraction, and ultrasonic extraction, preferably using a room temperature extraction or reflux extraction method May be, but is not limited to this.
  • the prepared extract can then be filtered or concentrated or dried to remove the solvent, it can be carried out both filtration, concentration and drying.
  • the filtration may use a filter paper or a vacuum filter
  • the concentration may be a vacuum concentrator
  • the drying may be a freeze-drying method, but is not limited thereto.
  • the extract extracted with the solvent may be further fractionated with a solvent selected from the group consisting of butanol, hexane, methylene chloride, acetone, ethyl acetate, ethyl ether, chloroform, water, and a mixed solvent thereof.
  • the fractionation temperature may be 4 °C to 120 °C, but is not limited thereto.
  • the following experiment was conducted to confirm the improvement or treatment effect of the Th2-mediated immune disease against the enzyme-treated Youngsil extract.
  • the enzyme-treated Youngsil extract or enzyme-treated Youngsil extract in mice immunized with OVA and compared the blood IgE content, the enzyme-treated Youngsil extract compared to the Youngsil extract administration group It was confirmed that the degree of IgE content reduction was enhanced in the administration group (see Example 3).
  • composition of the present invention can inhibit the production of IL-4 and IgE.
  • the pharmaceutical composition according to the present invention includes the enzyme-treated Youngsil extract as an active ingredient, and may further include a pharmaceutically acceptable carrier.
  • pharmaceutically acceptable carriers are conventionally used in the preparation, and include, but are not limited to, saline solution, sterile water, Ringer's solution, buffered saline, cyclodextrin, dextrose solution, maltodextrin solution, glycerol, ethanol, liposomes, and the like. If necessary, other conventional additives such as antioxidants and buffers may be further included.
  • diluents, dispersants, surfactants, binders, lubricants and the like may be additionally added to formulate injectable formulations, pills, capsules, granules or tablets such as aqueous solutions, suspensions, emulsions and the like.
  • Suitable pharmaceutically acceptable carriers and formulations can be preferably formulated according to the individual components using methods disclosed in Remington's literature.
  • the pharmaceutical composition of the present invention is not particularly limited in formulation, but may be formulated as an injection, inhalant, or external skin preparation.
  • compositions of the present invention can be administered orally or parenterally (eg, applied intravenously, subcutaneously, intraperitoneally or topically) according to the desired method, and the dosage is determined by the condition and weight of the patient, Depending on the extent, drug form, route of administration, and time, it may be appropriately selected by those skilled in the art.
  • the pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount.
  • pharmaceutically effective amount means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and an effective dose level refers to a disease type, severity, drug activity, drug, and drug of a patient. Sensitivity to, time of administration, route of administration and rate of release, duration of treatment, factors including concurrent use of drugs, and other factors well known in the medical arts.
  • the pharmaceutical compositions according to the present invention may be administered as individual therapeutic agents or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be single or multiple administrations. Taking all of the above factors into consideration, it is important to administer an amount that can obtain the maximum effect in a minimum amount without side effects, which can be easily determined by those skilled in the art.
  • the effective amount of the pharmaceutical composition of the present invention may vary depending on the age, sex, condition, weight of the patient, the absorption of the active ingredient in the body, the inactivation rate and excretion rate, the type of disease, the drug used in general 0.001 to 150 mg, preferably 0.01 to 100 mg per kg of body weight may be administered daily or every other day, or divided into 1 to 3 times a day.
  • the dosage may be increased or decreased depending on the route of administration, the severity of obesity, sex, weight, age, etc., and the above dosage does not limit the scope of the present invention in any way.
  • the present invention provides a health functional food composition for improving Th2-mediated immune disease, comprising an enzyme-treated Youngsil (Rosae multiflorae Fructus) extract as an active ingredient.
  • the term “improvement” means any action that at least reduces the parameters associated with the condition being treated, for example, the extent of symptoms.
  • the health functional food composition may be used simultaneously or separately with the agent for treatment before or after the onset of the disease in order to improve the Th2-mediated immune disease.
  • the term “health functional food composition” is selected from the group consisting of tablets, pills, powders, granules, powders, capsules, and liquid formulations, including one or more of carriers, diluents, excipients, and additives. Characterized in one.
  • Examples of the food that can be added to the extract of the present invention include various foods, powders, granules, tablets, capsules, syrups, beverages, gums, teas, vitamin complexes, and health functional foods.
  • additives which may be further included in the present invention, natural carbohydrates, flavoring agents, nutrients, vitamins, minerals (electrolytes), flavoring agents (synthetic flavoring agents, natural flavoring agents, etc.), colorants, fillers, pactic acid and salts thereof, Alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH regulators, stabilizers, preservatives, antioxidants, glycerin, alcohols, carbonation agents and one or more components selected from the group consisting of pulp can be used.
  • natural carbohydrates examples include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And conventional sugars such as polysaccharides such as dextrin, cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol.
  • natural flavoring agents tauumatin, stevia extract (for example, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used.
  • compositions according to the invention include various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic and natural flavors, colorants and neutralizers, fact acids and their salts, alginic acids and their salts, organic acids, protective colloidal thickeners , pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, etc.
  • other compositions of the present invention may contain flesh for the production of natural fruit juices and vegetable beverages.
  • carrier examples include, but are not limited to, lactose, dex , Sucrose, sorbitol, mannitol, erythritol, starch, acacia rubber, calcium phosphate, alginate, gelatin, calcium phosphate, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, polyvinylpyrrolidone, methylcellulose, water It is preferable to use at least one selected from the group consisting of sugar syrup, methyl hydroxy benzoate, propyl hydroxy benzoate, talc, magnesium stearate and mineral oil.
  • the present invention provides a cosmetic composition for improving Th2-mediated immune disease, comprising an enzyme-treated Youngsil (Rosae multiflorae Fructus) extract as an active ingredient.
  • the cosmetic composition of the present invention may include not only enzyme-treated Youngsil extract, but also components commonly used in cosmetic compositions, such as conventional auxiliaries such as antioxidants, stabilizers, solubilizers, vitamins, pigments, and perfumes, And a carrier.
  • conventional auxiliaries such as antioxidants, stabilizers, solubilizers, vitamins, pigments, and perfumes, And a carrier.
  • composition of the present invention may be used in addition to the enzyme-treated Youngsil extract, a mixture of organic sunscreens that have been conventionally used insofar as it does not impair the skin protection effect by reacting with the enzyme-treated Youngsil extract.
  • organic sunscreen examples include glyceryl pava, drometrizole trisiloxane, drometrizole, digaloyltrioleate, disodium phenyldibenzimidazole tetrasulfonate, diethylhexyl butamidotriazone, diethylamino Hydroxybenzoylhexylbenzoate, die-methoxycinnamate, a mixture of lowson and dihydroxyacetone, methylenebis-benzotriazolyltetramethylbutylphenol, 4-methylbenzylidene camphor, menthyl anthranilate, benzophenone -3 (oxybenzone), benzophenone-4, benzophenone-8 (dioxyphenbenzone), butylmethoxydibenzoylmethane, bisethylhexyloxyphenol methoxyphenyltriazine, synoxate, ethyldihydroxypropylpava, Oct
  • Examples of products to which the cosmetic composition of the present invention may be added include, for example, cosmetics such as astringent cosmetics, soft cosmetics, nourishing cosmetics, various creams, essences, packs, foundations, and the like, cleansing agents, soaps, treatments, and essences.
  • Specific formulations of the cosmetic composition of the present invention include skin lotion, skin softener, skin toner, astringent, lotion, milk lotion, moisture lotion, nutrition lotion, massage cream, nutrition cream, moisture cream, hand cream, essence, nutrition essence, pack, Formulations such as soaps, shampoos, cleansing foams, cleansing lotions, cleansing creams, body lotions, body cleansers, emulsions, lipsticks, makeup bases, foundations, press powders, loose powders, eye shadows and the like.
  • the content of the enzyme-treated Youngsil extract of the present invention is 0.00001-30% by weight, preferably 0.5-20%, more preferably 1.0-10% by weight based on the total weight of the composition. .
  • the content of the enzyme-treated Youngsil extract is less than 0.00001% by weight, the ultraviolet absorbing effect is greatly reduced, and when it exceeds 30% by weight, skin irritation may occur, and formulation problems may occur.
  • Youngsil was purchased from Tojong Village Co., Ltd. in Buyeosan, Chungcheongnam-do and used for experiment. Youngsil extract was prepared by three different types of extracts, namely, Youngsil water extract, Youngsil room temperature spirit extract, and Youngsil spirit water extract.
  • Youngsil water extract was obtained by mixing Youngsil and water in a weight ratio of 1:10, and then reflux extraction at 85 °C for 3 hours.
  • Youngsil room temperature ethanol extract was obtained by mixing Youngsil and ethanol (95% ethanol) in a weight ratio of 1:10, immersing in a shaking water bath, shaking at a speed of 45 rpm for 15 hours at 25 °C. .
  • the water extract after the Youngsil alcohol was obtained by recovering all the spirits after obtaining the Youngsil room temperature alcohol extract according to the above method, by adding reflux of 10 times the weight of the Youngsil residue to reflux extraction at 85 °C for 3 hours. Thereafter, the extracts were filtered, concentrated, and lyophilized using filter paper.
  • each Youngsil extract prepared by the method of 1-1 was dissolved in 50% DMSO (dimethyl sulfoxide) at a concentration of 100 mg / ml. , 0.05 M sodium acetate buffer (pH 5.0) was diluted to 10 mg / ml concentration. Each dilute Youngsil extract was treated with ⁇ -glucosidase at 10 units / ml, incubated at 37 ° C. for 24 hours, and each extract was used for the experiment.
  • DMSO dimethyl sulfoxide
  • OVA ovalbumin
  • red blood cell (RBC) lysing buffer SIGMA R7757
  • the 96-well plate was treated with an antigen of OVA at a concentration of 100 ⁇ g / ml, and each of the three types of Youngsil extracts prepared according to the method of Example 1-1 was 100, 200, or 400 ⁇ g / ml.
  • Each of the three types of Youngsil extract treated with ⁇ -glucosidase prepared according to the method of 1-2 was added at a concentration of 10, 50, 200 ⁇ g / ml, and the splenocytes of the mice cultured by the above method were added. Treated with 5 ⁇ 10 6 cells / well. After incubation for 72 hours in a CO 2 incubator at 37 °C cell culture was recovered.
  • IL-4 BD OptEIATM MOUSE enzyme-linked immunosorbent assay (ELISA) kit In order to measure the amount of IL-4 cytokines from the culture of mouse splenocytes recovered according to the method of Example 1-3, IL-4 BD OptEIATM MOUSE enzyme-linked immunosorbent assay (ELISA) kit and TGF- ⁇ kit The experiment was performed using (R & D Systems).
  • ELISA enzyme-linked immunosorbent assay
  • a capture antibody was added to a 96-well plate and reacted overnight at 4 ° C. to coat the plate with an antibody, washed with washing buffer (phosphate buffered saline with Tween20; PBST), and then assay diluent (10%).
  • FBS in PBS was added to each well and reacted at room temperature for 1 hour to perform a blocking process.
  • 100 ⁇ l of the culture solution of mouse splenocytes recovered through the standard solution and the method of Example 1-3 were dispensed into the wells, followed by reaction at room temperature for 2 hours.
  • IL-4 specific primary antibody capable of detecting IL-4 and a secondary antibody conjugated with streptavidin-horseradish peroxidase (streptoavidin-HRP) were injected into each well.
  • the reaction was performed at room temperature for 1 hour.
  • 100 ⁇ l of substrate solution (0.01% TMB in phosphate-citrate buffer) was added and developed for 30 minutes at room temperature.
  • 50 ⁇ l of 2 M H 2 SO 4 was added to each well to stop the color reaction. Absorbance was measured with a micro plate reader at nm.
  • the amount of IL-4 cytokines was measured from the culture medium of mouse splenocytes according to the methods of Examples 1-3 and 1-4. It was.
  • Example 2 Based on the results of Example 2, it was intended to evaluate the anti-allergic activity by enzyme-treated Youngsil extract in an in vivo allergy-induced mouse model. To this end, 10 ⁇ g of ovalbumin (OVA) and 1 mg of alum were mixed in 6-week-old BALB / c mice for 30 minutes, and then 100 ⁇ l per mouse 1 7 days and the first day of the experiment. And secondary immunization.
  • OVA ovalbumin
  • the total IgE amount was measured using BD mouse IgE ELISA kit.
  • IgE content was slightly reduced compared to the positive control group (Sham) even when administration of Youngsil extract (youngsil), ⁇ -glucosidase treated enzyme-treated Youngsil extract ( ⁇ -glucosidase treatment) ), The IgE content was significantly reduced compared to the administration of Youngsil extract.
  • composition for preventing, ameliorating, or treating a Th2-mediated immune disease is excellent in inhibiting Th2 immune response and inhibiting IgE production, thereby preventing, improving, or treating a Th2-mediated immune disease, preferably an allergic disease. It may be usefully used in industrial fields for the development of medicines, dietary supplements, and cosmetics.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Birds (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne une composition comprenant un extrait de fruit de Rosa multiflora traité par enzyme en tant que substance active pour prévenir ou traiter une maladie immunitaire médiée par Th2. La composition selon la présente invention peut maximiser l'effet antiallergique de l'extrait de fruit de Rosa multiflora en incluant un extrait de fruit de Rosa multiflora traité par enzyme en tant que substance active. Spécifiquement, les présents inventeurs ont vérifié que, en conséquence du traitement de splénocytes de souris immunisées par OVA avec un extrait de fruit de Rosa multiflora traité par enzyme, l'extrait de fruit de Rosa multiflora traité par enzyme stimule de façon remarquable l'activité inhibitrice de production d'IL-4 par rapport à un extrait de fruit de Rosa multiflora non traité par enzyme et l'administration orale in vivo de l'extrait de fruit de Rosa multiflora traité par enzyme réduit de façon remarquable la teneur en IgE dans le sang chez les souris immunisées par OVA. De plus, la composition selon la présente invention présente les avantages d'être biocompatible et d'avoir une excellente stabilité grâce à l'utilisation du fruit de Rosa multiflora en tant que matériau naturel, et donc, la composition devrait pouvoir être favorablement utilisée dans le développement d'un agent thérapeutique sûr, d'un aliment fonctionnel de santé, d'un produit cosmétique, et similaire pour la prévention, l'amélioration ou le traitement d'une maladie immunitaire médiée par Th2.
PCT/KR2016/013971 2015-12-09 2016-11-30 Composition comprenant un extrait de fruit de rosa multiflora traité par enzyme en tant que substance active pour prévenir ou traiter une maladie immunologique médiée par th2 WO2017099413A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20150174582 2015-12-09
KR10-2015-0174582 2015-12-09
KR10-2016-0160179 2016-11-29
KR1020160160179A KR101843573B1 (ko) 2015-12-09 2016-11-29 효소처리 영실 추출물을 유효성분으로 포함하는 Th2-매개 면역질환의 예방 또는 치료용 조성물

Publications (1)

Publication Number Publication Date
WO2017099413A1 true WO2017099413A1 (fr) 2017-06-15

Family

ID=59013430

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2016/013971 WO2017099413A1 (fr) 2015-12-09 2016-11-30 Composition comprenant un extrait de fruit de rosa multiflora traité par enzyme en tant que substance active pour prévenir ou traiter une maladie immunologique médiée par th2

Country Status (1)

Country Link
WO (1) WO2017099413A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070068837A (ko) * 2005-12-27 2007-07-02 일동제약주식회사 영실로부터 얻은 지방세포분화 억제용 활성 분획 조성물
KR20100111413A (ko) * 2009-04-07 2010-10-15 호서대학교 산학협력단 효소처리에 의한 연자육 추출물의 제조방법
WO2014088200A1 (fr) * 2012-12-06 2014-06-12 한국식품연구원 Composition pour prévenir, soulager ou traiter des maladies immunitaires, contenant de l'extrait de peau de truffe de virginie, de l'extrait de cynanchum atratum ou de l'extrait de arisaema amurense var. serratum en tant que substance active
KR20140073722A (ko) * 2012-12-06 2014-06-17 한국식품연구원 영실 추출물을 유효성분으로 포함하는 Ｔｈ2-매개 면역 질환의 예방, 개선 또는 치료용 조성물

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070068837A (ko) * 2005-12-27 2007-07-02 일동제약주식회사 영실로부터 얻은 지방세포분화 억제용 활성 분획 조성물
KR20100111413A (ko) * 2009-04-07 2010-10-15 호서대학교 산학협력단 효소처리에 의한 연자육 추출물의 제조방법
WO2014088200A1 (fr) * 2012-12-06 2014-06-12 한국식품연구원 Composition pour prévenir, soulager ou traiter des maladies immunitaires, contenant de l'extrait de peau de truffe de virginie, de l'extrait de cynanchum atratum ou de l'extrait de arisaema amurense var. serratum en tant que substance active
KR20140073722A (ko) * 2012-12-06 2014-06-17 한국식품연구원 영실 추출물을 유효성분으로 포함하는 Ｔｈ2-매개 면역 질환의 예방, 개선 또는 치료용 조성물

Similar Documents

Publication Publication Date Title
KR101051362B1 (ko) 생약재 발효산물을 포함하는 아토피성 피부염 치료 및/또는예방용 조성물
WO2019124863A1 (fr) Composition contenant comme principe actif un extrait de feuilles de schisandra chinensis destinée à la prévention, à l'amélioration et au traitement de la dermatite atopique
KR20200103564A (ko) 톳 추출물을 유효성분으로 포함하는 항염증 또는 항알러지용 조성물
WO2023177188A1 (fr) Composition cosmétique ayant des effets anti-inflammatoires et de barrière, comprenant un extrait de centella asiatica à l'état frais obtenu par extraction de sucre par diffusion, et son utilisation
KR101843574B1 (ko) 영실 발효 추출물을 유효성분으로 포함하는, Th2-매개 면역질환의 예방 또는 치료용 조성물
KR101756020B1 (ko) 물오리나무 발효추출물을 포함하는 아토피피부염 예방, 개선, 또는 치료용 조성물
KR102507470B1 (ko) 스트렙토코커스 피오게네스의 사균체 또는 SpeA 단백질을 포함하는 알레르기 질환의 예방 또는 치료용 약학적 조성물
KR101890017B1 (ko) 영실 및 황금 추출물을 유효성분으로 포함하는 Th2-매개 면역질환의 예방 또는 치료용 조성물
US20170135948A1 (en) Composition comprising extract of autumn soybean leaves
KR101483872B1 (ko) 신갈나무 잎 분획물을 포함하는 항주름용 조성물
WO2022124803A1 (fr) Composition destinée à la prévention, au soulagement ou au traitement de maladies allergiques, comprenant un extrait de spatholobus suberectus en tant que principe actif
KR101843573B1 (ko) 효소처리 영실 추출물을 유효성분으로 포함하는 Th2-매개 면역질환의 예방 또는 치료용 조성물
WO2017099413A1 (fr) Composition comprenant un extrait de fruit de rosa multiflora traité par enzyme en tant que substance active pour prévenir ou traiter une maladie immunologique médiée par th2
WO2017074058A1 (fr) Composition contenant un extrait de fermentation de rosa multiflora comme principe actif pour prévenir ou traiter des maladies immunitaires médiées par les th2
KR102144566B1 (ko) 택란 추출물을 유효성분으로 포함하는 아토피 피부염의 예방 또는 치료용 조성물
KR20100055952A (ko) 감잎으로부터 추출된 헬리코박터 파이로리균에 대한 항균성추출물
KR101838177B1 (ko) 효소처리 후추 추출물을 유효성분으로 포함하는 Th2-매개 면역질환의 예방 또는 치료용 조성물
WO2019078606A2 (fr) Composition anti-inflammatoire, antiallergène et améliorant la dermatite atopique utilisant un extrait de sargassum horneri ou un extrait d'ecklonia veine
KR102109503B1 (ko) 미?리아닌을 유효성분으로 포함하는 Th2-매개 면역질환의 예방 또는 치료용 조성물
KR102227261B1 (ko) 고욤 효소처리물을 유효성분으로 함유하는 아토피 피부염의 예방, 개선 또는 치료용 조성물
KR20190136543A (ko) 환삼덩굴 추출물을 유효성분으로 포함하는 발달장애 예방 또는 치료용 조성물
KR20190060631A (ko) 감태 추출물과 괭생이모자반 추출물을 이용한 아토피 피부염 개선용 조성물
KR101838178B1 (ko) 후추 발효 추출물을 유효성분으로 포함하는 Th2-매개 면역질환의 예방 또는 치료용 조성물
KR102607144B1 (ko) 효소처리 엘라그산을 유효성분으로 포함하는 Th2-매개 면역질환 또는 염증성 질환의 예방 또는 치료용 조성물
WO2019045286A2 (fr) Composition comprenant de la miquelianine en tant que principe actif pour la prévention ou le traitement d'une maladies immunitaire médiée par th2

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16873278

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16873278

Country of ref document: EP

Kind code of ref document: A1